# EDGAR Filing Document

**Accession Number:** 0001739426
**File Stem:** 9999999997-23-000870
**Filing Date:** 2023-3
**Character Count:** 2436
**Document Hash:** e5ab4dfaddbd383de571a528f9088fd7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999997-23-000870.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 9999999997-23-000870

**CONFORMED SUBMISSION TYPE**: CT ORDER

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**ACTION DATE**: 20230308

**RECEIVED DATE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RVL Pharmaceuticals plc
- **CENTRAL INDEX KEY:** 0001739426
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CT ORDER
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-227357
- **FILM NUMBER:** 23715191

**BUSINESS ADDRESS:**
- **STREET 1:** 400 CROSSING BOULEVARD
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 9088091300

**MAIL ADDRESS:**
- **STREET 1:** 400 CROSSING BOULEVARD
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Osmotica Pharmaceuticals plc
- **DATE OF NAME CHANGE:** 20180906

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Osmotica Pharmaceuticals Ltd
- **DATE OF NAME CHANGE:** 20180502

### Attached PDF Documents

**Attachment 1:** `filename1`

# **UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 8, 2023**

# **ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933**

**RVL Pharmaceuticals plc**

**File No. 333-227357 - CF#36385**

RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc) submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on September 14, 2018, as amended on October 1, 2018 and October 17, 2018.

Based on representations by RVL Pharmaceuticals plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| Exhibit 10.18 | through May 10, 2028 |
| --- | --- |
| Exhibit 10.19 | through May 10, 2028 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Chief, Knowledge Management Office